The IGFBP5 Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional disruption of the IGFBP5 gene. This product provides a heterogeneous loss-of-function model derived from the CAL-27 host cell line, enabling investigation of IGFBP5-dependent signaling in oral squamous cell carcinoma.
The CAL-27 cell line is derived from a human tongue squamous cell carcinoma and is a widely used epithelial model for oral cancer research. It retains characteristic features of oral squamous cell carcinoma, including aggressive growth and invasive potential, making it suitable for migration, invasion, and drug response assays.
IGFBP5 encodes a secreted IGF-binding protein that modulates the bioavailability of insulin-like growth factors IGF1 and IGF2, thereby regulating IGF-1 receptor signaling. The protein interacts with IGF1, IGF2, fibronectin (FN1), integrins ITGAV/ITGB3, and LRP1. Upstream regulators include TP53, TGFB1, cortisol, vitamin D, and ESR1, which influence IGFBP5 expression through transcriptional and epigenetic mechanisms. Downstream, loss of IGFBP5 disrupts key signaling cascades, including the PI3K/AKT pathway (via IGF1, IGF1R, IRS1, PIK3CA, AKT1, MTOR) and the MAPK/ERK pathway (via SHC1, GRB2, MAPK1/3). This affects cell cycle regulators like CDKN1A (p21) and matrix remodeling enzymes such as MMP2, ultimately altering cell proliferation, apoptosis, and migration.
In CAL-27 cells, where autocrine IGF signaling supports tumor cell survival and motility, IGFBP5 knockout disrupts the local regulation of IGF availability, potentially reducing activation of AKT1 and ERK1/2. This may impair proliferative and migratory capacity while modulating apoptotic sensitivity. Given the context-dependent dual role of IGFBP5 in cancer, the polyclonal knockout model allows researchers to evaluate these functions without clonal bias, capturing a range of editing outcomes and reflecting population-level responses.
Typical applications include functional genomics, drug sensitivity studies targeting the IGF axis, migration and invasion assays, tumor microenvironment interaction studies, and analysis of PI3K/AKT and MAPK pathway perturbations. Representative assays include western blotting, RT-qPCR, RNA-seq, flow cytometry, apoptosis and proliferation assays, co-immunoprecipitation, and migration/invasion assays. This product is an ideal tool for cancer biologists and pharmacologists investigating IGFBP5 function in oral squamous cell carcinoma. For further technical specifications or ordering information, please contact Ascent Research.
